Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Inclusion Criteria:

- Patients with early or advanced idiopathic Parkinson's Disease

- Patients with advanced idiopathic Parkinson's Disease: intake of Levodopa on a stable
dose of at least 200 mg/day

- Unsatisfactory control of Parkinson's Disease motor symptoms under current treatment

- Patients experiencing Apathy associated with Parkinson's Disease

- Hoehn and Yahr stage score of I to IV

- Mini-Mental State Examination score ≥ 25

- If an antidepressant drug is taken, the dose must be stable

Exclusion Criteria:

- Therapy with a Dopamine agonist

- Discontinuation from pervious therapy with a dopamine agonist after an adequate length
of treatment, at adequate dose, due to lack of efficacy

- Any medical or psychiatric condition that jeopardizes / compromises patient's ability
for participation

- Patient has received Neuroleptics, Dopamine releasing substances, Dopamine modulating
substances, Alpha-Methyldopa, Metoclopramide, MAO-A inhibitors, Budipine, or Tolcapone

- Electroconvulsive therapy

- Patient has a

- current/anticipated psychotherapy or behavior therapy

- history of deep brain stimulation

- history of suicide attempt or has suicidal ideation

- impulse control disorder

- severe Depression